UNRESECTABLE THYROID GLAND CARCINOMA
Clinical trials for UNRESECTABLE THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to tame aggressive thyroid cancer
Disease control OngoingThis study is testing whether two drugs, lenvatinib and pembrolizumab, work better together for people with advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. Lenvatinib aims to block tumor growth, while pembrolizumab helps the body's immune syste…
Matched conditions: UNRESECTABLE THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Scientists test new drug duo against tough thyroid cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a two-drug combination (dabrafenib and lapatinib) for adults with advanced thyroid cancer that has a specific genetic change (BRAF mutation) and has stopped responding to standard treatments. The main goal is to see ho…
Matched conditions: UNRESECTABLE THYROID GLAND CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for fighting rare, Fast-Growing thyroid cancer
Disease control OngoingThis study is testing whether combining a drug that helps the immune system fight cancer (atezolizumab) with different chemotherapy drugs can help people with aggressive forms of thyroid cancer that have spread or cannot be removed by surgery. The goal is to see if this combinati…
Matched conditions: UNRESECTABLE THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC